Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

851
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
851
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Synthesis and Biological Evaluation of 4‑Bromo-<i>N,N-</i>dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.

ACS omega·2026
Same author

ASO Author Reflections: Atypical Breast Lesions on Core Needle Biopsy: Defining a Low-Risk Population to Guide Selective Surgical Excision.

Annals of surgical oncology·2026
Same author

Risk Stratification of Atypical Breast Lesions Diagnosed on Core Needle Biopsy: Toward Selective Surgical Excision.

Annals of surgical oncology·2026
Same author

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.

Journal of pharmaceutical and biomedical analysis·2026
Same author

α-Synuclein and γ-Tubulin Cooperatively Regulate Activity-Evoked Presynaptic Microtubule Nucleation to Gate Dopamine Release.

bioRxiv : the preprint server for biology·2026
Same author

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs.

ACS chemical neuroscience·2026

関連する実験動画

Updated: Jan 7, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K

イボガインのマトリックス薬理解読:セロトニンシナプスの複数のトランスポーター調節

Christopher Hwu1, Václav Havel1, Xavier Westergaard2,3

  • 1Department of Chemistry, Columbia University, New York, New York 10027, United States.

Journal of the American Chemical Society
|December 26, 2025
PubMed
まとめ

イボガインとその代謝産物ノリボガインは,膀性モノアミントランスポーター2 (VMAT2) とセロトニントランスポーター (SERT) を阻害する. "シナプス再吸収阻害剤" (SynRIs) と呼ばれるこの二重作用は,イボガインの

さらに関連する動画

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

関連する実験動画

Last Updated: Jan 7, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

科学分野:

  • 神経科学
  • 薬理学について
  • 生物化学

背景:

  • イボガインはイボガの木から派生し,様々な神経学的および精神的疾患の治療の可能性を示しています.
  • 作用のメカニズムを理解するには,モノアミンの神経伝達体への影響を調べる必要があります.

研究 の 目的:

  • イボガイン,ノリボガイン,イボガイン類のモノアミントランスポーターに対する効果を体系的に調査する.
  • イボガインの治療効果の 基礎となる神経化学的メカニズムを解明する

主な方法:

  • VMAT2輸送機能を評価するための細胞ベースの光測定法.
  • 2光子顕微鏡で マウスの脳内のトランスポーター活動を可視化します
  • 放射性標識されたセロトニンを用いて脳シナプス小胞で吸収と放出を測定する.
  • SERTとOCT2を含むプラズマ膜モノアミントランスポーター (MAT) の抑制測定

主要な成果:

  • イボガインとノリボガインはVMAT2を微小分子の効能で抑制する.
  • ノリボガインは,シナプス水泡からセロトニンの部分的な放出を誘導することが判明しました.
  • イボガ化合物はSERTとOCT2を阻害し,いくつかの類似体はVMAT2とSERTの二重阻害を示しています.
  • これらの二重阻害剤は"シナプス再吸収阻害剤" (SynRIs) と呼ばれた.

結論:

  • SynRIプロファイルは,イボガインの神経化学効果と治療の可能性のモデルを提供します.
  • この"マトリックス薬理"と呼ばれるイボガインの最新理解は,なぜイボガインが他のVMAT2阻害剤と異なり,カタレプシーを誘発しないかを説明するのに役立ちます.